Hospital
Steward ST. Elizabeth's Medical Center of Boston, INC.
Steward ST. Elizabeth's Medical Center of Boston, INC. was paid $32.53M by Medicaid between Jan 2018 and Dec 2024, across 295 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoSTEWARD ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC.
BOSTON, MA 02135
BOSTON, MA 02135
33aNPI1720390289assigned 07/12/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.53M
24GClaims727,873
24DCodes billed295
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#32 of 66
Median peer was paid$29.11M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RENNA, JAMES controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 123,080 | $5.37M | |
| 2019 | 113,335 | $4.48M | |
| 2020 | 94,505 | $4.09M | |
| 2021 | 119,006 | $5.38M | |
| 2022 | 111,171 | $5.30M | |
| 2023 | 103,210 | $4.70M | |
| 2024incomplete | 63,566 | $3.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 27,371 | 24,238 | $4.06M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.7% | 19,694 | 17,474 | $2.84M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.0% | 17,507 | 15,771 | $2.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 14,684 | 12,945 | $2.17M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.4% | 15,815 | 14,571 | $2.07M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.8% | 5,274 | 4,572 | $1.90M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.7% | 9,810 | 6,697 | $1.54M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.9% | 45,362 | 37,324 | $1.26M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.9% | 5,960 | 5,176 | $937K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 4,562 | 4,246 | $614K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.8% | 896 | 877 | $580K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 1,022 | 992 | $556K |
283 more codes
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.6% | 3,715 | $532K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 3,458 | $468K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 3,228 | $417K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 7,185 | $405K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.2% | 2,306 | $376K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 3,550 | $343K |
| 59025 | Fetal non-stress test | <1% | 1,286 | $319K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,396 | $319K |
| 20610 | <1% | 2,308 | $303K | |
| 31231 | <1% | 1,345 | $298K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,451 | $293K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,050 | $290K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,810 | $285K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,733 | $282K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,910 | $238K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,927 | $219K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,459 | $212K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,739 | $193K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,847 | $166K |
| G0378 | Hospital observation service, per hour | <1% | 8,750 | $165K |
| 93971 | <1% | 853 | $152K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,832 | $142K |
| 76830 | Ultrasound, transvaginal | <1% | 1,409 | $131K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,016 | $130K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,625 | $128K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,235 | $127K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 225 | $127K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 902 | $122K |
| 31256 | <1% | 66 | $116K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,912 | $114K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,932 | $114K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 875 | $110K |
| 87428 | <1% | 1,909 | $97K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 903 | $95K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,456 | $95K |
| 64493 | <1% | 181 | $95K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,658 | $93K |
| 76801 | <1% | 861 | $91K | |
| 30520 | <1% | 67 | $86K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,677 | $85K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 222 | $85K |
| ATP14 | <1% | 8,915 | $81K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,016 | $77K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,016 | $75K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,844 | $73K |
| 93970 | <1% | 313 | $72K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 63 | $72K |
| 62323 | <1% | 191 | $71K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 450 | $68K |
| 31254 | <1% | 53 | $64K | |
| 93017 | <1% | 683 | $61K | |
| 76642 | <1% | 521 | $60K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,376 | $60K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,050 | $58K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 944 | $56K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 268 | $48K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,672 | $46K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,769 | $45K |
| 71250 | <1% | 712 | $43K | |
| 90688 | <1% | 2,270 | $42K | |
| 80053 | Comprehensive metabolic panel | <1% | 20,746 | $41K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,311 | $40K |
| 84484 | <1% | 8,039 | $40K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 222 | $38K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,771 | $38K |
| ATP08 | <1% | 5,781 | $38K | |
| 73630 | <1% | 2,512 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,552 | $37K |
| 90715 | <1% | 1,663 | $36K | |
| 87631 | <1% | 424 | $36K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 68 | $35K |
| 84702 | <1% | 2,943 | $34K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 285 | $33K |
| 86850 | <1% | 5,305 | $31K | |
| 81025 | <1% | 5,812 | $31K | |
| 76536 | <1% | 287 | $31K | |
| 76770 | <1% | 200 | $29K | |
| 92557 | <1% | 744 | $29K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,234 | $28K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,088 | $28K |
| 73562 | <1% | 2,859 | $27K | |
| 76775 | <1% | 327 | $27K | |
| 77080 | <1% | 598 | $26K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,905 | $26K |
| 31575 | <1% | 154 | $25K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 131 | $24K |
| 97161 | <1% | 572 | $24K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,959 | $23K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,718 | $22K |
| 83735 | <1% | 6,607 | $22K | |
| 85027 | <1% | 5,724 | $21K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,233 | $20K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 344 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,429 | $20K |
| 83690 | <1% | 4,453 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,781 | $20K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,091 | $19K |
| 81001 | <1% | 10,020 | $19K | |
| 97162 | <1% | 496 | $19K | |
| 99219 | <1% | 30 | $17K | |
| 86900 | <1% | 5,418 | $17K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 58 | $16K |
| Q3014 | Telehealth originating site facility fee | <1% | 5,547 | $15K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 925 | $15K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 148 | $14K |
| 87070 | <1% | 2,938 | $14K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 355 | $14K |
| ATP15 | <1% | 1,570 | $13K | |
| 90750 | <1% | 366 | $13K | |
| 83880 | <1% | 1,185 | $13K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 932 | $13K |
| 95886 | <1% | 66 | $12K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,997 | $12K |
| 93925 | <1% | 90 | $12K | |
| 76857 | <1% | 242 | $11K | |
| 86901 | <1% | 5,389 | $11K | |
| 73030 | <1% | 1,688 | $11K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,173 | $11K |
| 85610 | <1% | 6,199 | $11K | |
| 73502 | <1% | 1,017 | $10K | |
| 72100 | <1% | 536 | $10K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 556 | $10K |
| 92567 | <1% | 824 | $9K | |
| 87186 | <1% | 1,893 | $9K | |
| 73610 | <1% | 1,621 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,323 | $9K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 134 | $9K |
| 85730 | <1% | 2,998 | $9K | |
| 73130 | <1% | 1,203 | $9K | |
| 84600 | <1% | 925 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,663 | $8K |
| 81003 | <1% | 6,593 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 455 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 71 | $8K |
| 12001 | <1% | 39 | $8K | |
| 81513 | <1% | 93 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,318 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,087 | $7K |
| 70486 | <1% | 135 | $6K | |
| 69210 | <1% | 286 | $6K | |
| 97803 | <1% | 137 | $6K | |
| 30802 | <1% | 56 | $6K | |
| 87205 | <1% | 2,264 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,483 | $6K |
| 87899 | <1% | 630 | $6K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 5,237 | $6K |
| 83605 | <1% | 1,172 | $6K | |
| 87077 | <1% | 1,061 | $6K | |
| 88307 | <1% | 64 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,086 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,758 | $5K |
| 86703 | <1% | 519 | $5K | |
| 20550 | <1% | 34 | $5K | |
| 80050 | General health panel | <1% | 484 | $5K |
| 99205 | Prolong outpt/office vis | <1% | 26 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 470 | $5K |
| 82947 | <1% | 6,847 | $4K | |
| 87486 | <1% | 165 | $4K | |
| 86803 | <1% | 360 | $4K | |
| 73110 | <1% | 749 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 202 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,059 | $3K |
| 88304 | <1% | 601 | $3K | |
| 86592 | <1% | 818 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,465 | $3K |
| 87040 | <1% | 665 | $3K | |
| 87481 | <1% | 105 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,746 | $2K |
| 74178 | <1% | 12 | $2K | |
| 86140 | <1% | 911 | $2K | |
| 93880 | <1% | 27 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $2K |
| 90662 | <1% | 482 | $2K | |
| 82565 | <1% | 1,883 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,418 | $2K |
| 90677 | <1% | 73 | $2K | |
| 97802 | <1% | 26 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 21 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,101 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 35 | $2K |
| 87081 | <1% | 309 | $2K | |
| 0064A | <1% | 76 | $2K | |
| 88342 | <1% | 1,498 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 599 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $1K |
| 85379 | <1% | 261 | $1K | |
| 20553 | <1% | 12 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,702 | $1K |
| 73140 | <1% | 177 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 625 | $1K |
| 71271 | <1% | 27 | $1K | |
| 85652 | <1% | 868 | $1K | |
| 86787 | <1% | 99 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,541 | $1K |
| 84100 | <1% | 3,717 | $980.48 | |
| 64494 | <1% | 242 | $974.58 | |
| 82728 | <1% | 145 | $969.92 | |
| ATP02 | <1% | 298 | $929.41 | |
| 84439 | <1% | 154 | $918.46 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 336 | $873.90 |
| 90674 | <1% | 48 | $823.14 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 365 | $798.71 |
| 82570 | <1% | 283 | $776.62 | |
| 87807 | <1% | 75 | $773.85 | |
| 77066 | Tomosynthesis, mammo | <1% | 27 | $773.80 |
| 87340 | <1% | 96 | $676.52 | |
| 90739 | <1% | 38 | $630.45 | |
| 82607 | <1% | 99 | $627.35 | |
| 88313 | <1% | 799 | $624.25 | |
| 97166 | <1% | 18 | $610.46 | |
| 87147 | <1% | 101 | $581.72 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 22 | $576.18 |
| 88112 | <1% | 13 | $557.46 | |
| 88142 | <1% | 36 | $543.95 | |
| ATP09 | <1% | 109 | $537.60 | |
| 11720 | <1% | 17 | $498.71 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,086 | $497.54 |
| J3490 | Unclassified drugs | <1% | 337 | $486.37 |
| 85007 | <1% | 261 | $424.65 | |
| 90686 | <1% | 12 | $326.50 | |
| 84703 | <1% | 67 | $313.68 | |
| 85014 | <1% | 212 | $288.24 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 763 | $270.38 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,392 | $249.70 |
| 82553 | <1% | 38 | $248.54 | |
| 73080 | <1% | 65 | $233.73 | |
| 74018 | <1% | 30 | $224.94 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,444 | $179.64 |
| 80076 | <1% | 1,989 | $177.39 | |
| 87480 | <1% | 13 | $176.80 | |
| 86762 | <1% | 12 | $133.56 | |
| 84156 | <1% | 44 | $126.07 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 282 | $118.26 |
| 93280 | <1% | 37 | $112.49 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15 | $78.33 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 614 | $78.09 |
| 88341 | <1% | 14 | $77.29 | |
| 73560 | <1% | 14 | $76.07 | |
| 82040 | <1% | 180 | $59.52 | |
| 36416 | <1% | 1,725 | $53.48 | |
| 82746 | <1% | 12 | $51.88 | |
| 76000 | <1% | 15 | $38.88 | |
| 84153 | <1% | 12 | $32.44 | |
| ATP03 | <1% | 12 | $27.40 | |
| 83540 | <1% | 13 | $22.84 | |
| 99406 | <1% | 99 | $20.57 | |
| 84550 | <1% | 76 | $12.89 | |
| 80061 | Lipid panel | <1% | 1,831 | $12.21 |
| 83615 | <1% | 226 | $11.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 56 | $7.04 |
| 82550 | <1% | 40 | $6.71 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 132 | $0.64 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 68 | $0.00 |
| C1769 | Guide wire | 0% | 882 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 124 | $0.00 |
| 96376 | 0% | 224 | $0.00 | |
| 94760 | 0% | 210 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,555 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 442 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 122 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 706 | $0.00 |
| 84132 | 0% | 14 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 263 | $0.00 |
| C9046 | Cocaine hydrochloride nasal solution (goprelto), 1 mg | 0% | 12 | $0.00 |
| 80320 | 0% | 284 | $0.00 | |
| 73564 | 0% | 13 | $0.00 | |
| 91306 | 0% | 33 | $0.00 | |
| G0268 | Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing | 0% | 12 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 16 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 73 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 12 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 67 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 561 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 219 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 266 | $0.00 |
| 84145 | 0% | 33 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 63 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 163 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 174 | $0.00 |
| 77002 | 0% | 12 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 74 | $0.00 |
| 88312 | 0% | 46 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRENNA, JAMES (CHIEF FINANCIAL OFFICER)
Parent organizationSTEWARD HEALTH CARE SYSTEM LLC
| Provider | Location | Paid |
|---|---|---|
| Steward Holy Family Hospital, INC. | Methuen, MA | $70.80M |
| Steward Good Samaritan Medical Center, INC. | Brockton, MA | $64.10M |
| Steward Carney Hospital, INC. | Dorchester Center, MA | $56.76M |
| Steward Norwood Hospital, INC. | Norwood, MA | $8.47M |
| Steward ST. Elizabeth's Medical Center of Boston, INC. | Boston, MA | $1.90M |
| Steward Holy Family Hospital, INC. | Methuen, MA | $1.06M |
| New England Sinai Hospital, a Steward Family Hospital, INC. | Stoughton, MA | $136K |
| Steward Carney Hospital, INC. | Dorchester Center, MA | $52K |
| Steward Good Samaritan Medical Center, INC. | Brockton, MA | $29K |
| Morton Hospital, a Steward Family Hospital, INC. | Taunton, MA | $11K |
| Steward ST. Anne's Hospital Corporation | Fall River, MA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.